Core Insights - MEDIPOST has secured an $8 million upfront payment for the joint commercialization of its stem cell therapy CARTISTEM in Japan, targeting knee osteoarthritis [1][2] - The partnership with Teikoku Seiyaku Co., Ltd. includes exclusive sales, distribution, and promotion rights for CARTISTEM in Japan, while MEDIPOST retains manufacturing rights [2][3] - CARTISTEM has been administered to over 35,000 patients since its regulatory approval in South Korea in 2012 and is designed to regenerate cartilage in knee osteoarthritis patients [4] Company Overview - MEDIPOST, founded in 2000, is a global stem cell therapy company with capabilities in discovery research, clinical development, and cell and gene therapy contract development and manufacturing [5] - Teikoku Seiyaku, established in 1848, focuses on transdermal drug delivery technology and has a mission to alleviate pain, with ongoing efforts in the orthopedic sector [6][7] Market Strategy - Teikoku Seiyaku plans to utilize its extensive orthopedic hospital and clinic network to promote CARTISTEM, aiming to address unmet medical needs in knee osteoarthritis treatment in Japan [3][6] - The company is expanding its medical representative division to enhance the promotion of CARTISTEM ahead of its approval [3]